BRAF and gallbladder carcinoma: Therefore, when considering the relationship between FAM83H/ZNF16 and tyrosine kinase- and BRAF-pathways, the inhibitors of the tyrosine kinase receptor and BRAF might be useful for the treatment of the poor prognostic subgroup of gallbladder carcinoma with high expression of FAM83H/ZNF16 [31, 32].